Relation between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Presence and Severity of Erectile Dysfunction

Abstract

Previous studies have evidenced that inflammation and endothelial dysfunction have a crucial role in erectile dysfunction (ED). Increased monocyte count or activity and lower high-density lipoprotein cholesterol (HDL-C) levels have been associated with inflammation. The monocyte to HDL-C ratio (MHR) is a recently emerged indicator of inflammation. We aimed to investigate the relationship between MHR and ED. In this retrospective study, a total of 120 patients were enrolled, 60 of them having ED and 60 having a normal erectile function. The presence of ED was evaluated with the International Index of Erectile Function (IIEF-5). Patients with ED were compared with the control group for IIEF-5 and MHR. The mean ages of patients and controls were 55.6±5.53 and 56.42±6.63 years, respectively (p = 0.47). The risk factors for ED were similar between cases and controls. The total testosterone, glucose and creatinine levels did not differ between groups. While the HDL-C, LDL-C and triglyceride levels were similar between groups, the monocyte count (0.55±0.20 vs. 0.73±0.18, p < 0.0001) and MHR was significantly greater in patients with ED than in those without ED (1.31 vs. 1.77, p < 0.0001). MHR was significantly negatively correlated with IIEF-5 (p < 0.0001). To our knowledge, this is the first study that has shown a significant and independent association between elevated MHR and ED.

Keywords

erectile dysfunction - monocyte - high-density lipoprotein - endothelial dysfunction - inflammation

• References

• 1 NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90
• 2 Feldman HA, Goldstein I, Hatzichristou DG. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
• 3 Simonsen U, Garcia-Sacristan A, Prieto D. Penile arteries and erection. J Vasc Res 2002; 39: 283-303
• 4 Vlachopoulos C, Rokkas K, Ioakeimidis N. et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol 2005; 48: 996-1002 discussion 1002–1003
• 5 Corona G, Mannucci E, Petrone L. et al. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007; 4: 789-796
• 6 Thompson IM, Tangen CM, Goodman PJ. et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002
• 7 Ponholzer A, Temml C, Obermayr R. et al. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke?. Eur Urol 2005; 48: 512-518 discussion 517-518
• 8 Chang ST, Chu CM, Hsu JT. et al. Surveillance of cardiovascular risk factors for outpatients in different erectile dysfunction severity. Int J Impot Res 2009; 21: 116-121
• 9 Gupta BP, Murad MH, Clifton MM. et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011; 171: 1797-1803
• 10 Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7: 803-815
• 11 Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. Endothelium 2006; 13: 423-429
• 12 Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-126
• 13 Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047
• 14 Geissmann F, Manz MG, Jung S. et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661
• 15 Hessler JR, Robertson Jr AL, Chisolm 3rd GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32: 213-229
• 16 Li XP, Zhao SP, Zhang XY. et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 2000; 73: 231-236
• 17 Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044: 275-283
• 18 Westerterp M, Gourion-Arsiquaud S, Murphy AJ. et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012; 11: 195-206
• 19 Wang N, Lan D, Chen W. et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004; 101: 9774-9779
• 20 Kanbay M, Solak Y, Unal HU. et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014; 46: 1619-1625
• 21 Canpolat U, Aytemir K, Yorgun H. et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2015; 17: 1807-1815
• 22 Canpolat U, Cetin EH, Cetin S. et al. Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation. Clin Appl Thromb Hemost 2016; 22: 476-482
• 23 Rosen RC, Riley A, Wagner G. et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830
• 24 Vlachopoulos C, Rokkas K, Ioakeimidis N. et al. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007; 52: 1590-1600
• 25 Shah NP, Cainzos-Achirica M, Feldman DI. et al. Cardiovascular Disease Prevention in Men with Vascular Erectile Dysfunction: The View of the Preventive Cardiologist. Am J Med 2016; 129: 251-259
• 26 Kloner RA. Erectile dysfunction as a predictor of cardiovascular disease. Int J Impot Res 2008; 20: 460-465
• 27 Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-48L
• 28 Castela A, Costa C. Molecular mechanisms associated with diabetic endothelial-erectile dysfunction. Nat Rev Urol 2016; 13: 266-274
• 29 Steinberg D, Parthasarathy S, Carew TE. et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924
• 30 Murphy AJ, Woollard KJ, Hoang A. et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28: 2071-2077
• 31 Kratzer A, Giral H, Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res 2014; 103: 350-361
• 32 Kuvin JT, Ramet ME, Patel AR. et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144: 165-172
• 33 Yuhanna IS, Zhu Y, Cox BE. et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7: 853-857
• 34 Roumeguere T, Wespes E, Carpentier Y. et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; 44: 355-359
• 35 Cicek G, Kundi H, Bozbay M. et al. The relationship between admission monocyte HDL-C ratio with short-term and long-term mortality among STEMI patients treated with successful primary PCI. Coron Artery Dis 2016; 27: 176-184
• 36 Kundi H, Gok M, Kiziltunc E. et al. Relation Between Monocyte to High-Density Lipoprotein Cholesterol Ratio With Presence and Severity of Isolated Coronary Artery Ectasia. Am J Cardiol 2015; 116: 1685-1689
• 37 Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77-86